Jing Wang

Jing Wang

Auto-generated profile, based on publicly available information

Jing Wang

Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China; Department of Pediatric Cardiovascular, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Experimental Cell Research
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
YCYinghui Chen
Yinghui Chen
ZZZhaoxiang Zeng
Zhaoxiang Zeng
RFRui Feng
Rui Feng
QWQing Wang
Qing Wang
YYYu Yu
Yu Yu

1 January 2016 in Neural Regeneration Research
Verified
Journal Article
Open access
SZSonglin Zhou
Songlin Zhou
TQTianmei Qian
Tianmei Qian
LZLili Zhao
Lili Zhao
JWJing Wang
Jing Wang
Ping LiPing Li
Ping Li
XGXiaosong Gu
Xiaosong Gu
MicroRNAs (miRNAs) are small, non-coding RNAs that negatively adjust gene expression in multifarious biological processes. However, the regulatory effects of miRNAs on Schwann cells remain poorly understood. Previous microarray analysis results have shown that miRNA expression is altered following sciatic nerve transaction, thereby affecting proliferation and migration of Schwann cells. This study investigated whether miR-148b-3p could regulate migration of Schwann cells by directly targeting cullin-associated and neddylation-dissociated 1 (Cand1). Up-regulated expression of miR-148b-3p promoted Schwann cell migration, whereas silencing of miR-148b-3p inhibited Schwann cell migration in vitro. Further experiments confirmed that Cand1 was a direct target of miR-148b-3p, and Cand1 knockdown reversed suppression of the miR-148b-3p inhibitor on Schwann cell migration. These results suggested that miR-148b-3p promoted migration of Schwann cells by directly targeting Cand1 in vitro.

1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LJLihui Jin
Lihui Jin
NHNanchao Hong
Nanchao Hong
XAXuefeng Ai
Xuefeng Ai
JWJing Wang
Jing Wang
ZLZhuoyan Li
Zhuoyan Li
KSKun Sun
Kun Sun
Background: Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. The concept of precision medicine in CVD therapy today requires the incorporation of individual genetic and environmental variability to achieve personalized disease prevention and tailored treatment. Autophagy, an evolutionarily conserved intracellular degradation process, has been demonstrated to be essential in the pathogenesis of various CVDs. Nonetheless, there have been no effective treatments for autophagy- involved CVDs. Long noncoding RNAs (lncRNAs) are noncoding RNA sequences that play versatile roles in autophagy regulation, but much needs to be explored about the relationship between lncRNAs and autophagy-involved CVDs. Summary: Increasing evidence has shown that lncRNAs contribute considerably to modulate autophagy in the context of CVDs. In this review, we first summarize the current knowledge of the role lncRNAs play in cardiovascular autophagy and autophagy-involved CVDs. Then, recent developments of antisense oligonucleotides (ASOs) designed to target lncRNAs to specifically modulate autophagy in diseased hearts and vessels are discussed, focusing primarily on structure-activity relationships of distinct chemical modifications and relevant clinical trials. Perspective: ASOs are promising in cardiovascular drug innovation. We hope that future studies of lncRNA-based therapies would overcome existing technical limitations and help people who suffer from autophagy-involved CVDs.